BeyondSpring Inc. (BYSI, Financial), a clinical-stage biopharmaceutical company focusing on cancer therapies, experienced a significant stock price drop of 5.83%. The share price is currently at $2.10, with a trading volume of 15,265 shares and a turnover rate of 0.04%. The stock's amplitude is 3.14%.
In its latest financial report, BeyondSpring reported revenues of $1,000,000 and a net loss of $7.26 million. The company's earnings per share are at a negative $0.19, and its price-to-earnings ratio stands at negative 5.32. As of now, no institutional ratings for "buy," "hold," or "sell" are available for this stock.
The broader biotechnology industry saw a decline of 0.35%, while certain stocks in the sector, such as Neurogene Inc., Tenaya Therapeutics, Inc., and Disc Medicine, Inc., showed substantial gains. Meanwhile, Elevai Labs, Inc., Nls Pharmaceutics Ltd., and Gri Bio, Inc. were notably active, with turnover rates of 445.28%, 284.01%, and 98.20% respectively. Notably volatile stocks included Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com), Ocean Biomedical Inc C/Wts 14/02/2028 (To Pur Com), and In8Bio, Inc., with amplitudes of 52.25%, 45.56%, and 45.39%, respectively.
BeyondSpring Inc. is focused on developing cancer therapies with a specific emphasis on immuno-oncology drugs. The company operates through two principal segments: the Plinabulin pipeline and the TPD platform.
